Improving the Quality of Substance Dependency Treatment with Pharmacotherapy

References

• Agricola R. Treatment of acute alcohol withdrawal syndrome with carbamazepine: A double-blind comparison with tiapride. J. Int. Med. Res. 1982; 10: 160–165
   PubMed Web of Science ®Google Scholar
• Amass L., Bickel W. K., Crean J. P., Blake J., Higgins S. T. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology 1998; 136: 217–225
   PubMed Web of Science ®Google Scholar
• Amass L., Bickel W. K., Higgins S. T., Badger G. J. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci. 1994; 54: 1215–1228
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders: Alcohol, cocaine, opioids. Am. J. Psychiatry 1995; 152(Suppl)5–59
   Google Scholar
• Arndt I. O., Dorozynsky L., Woody G. E., McLellan A. T., O'Brien C. P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch. Gen. Psychiatry 1992; 49: 888–893
   PubMed Web of Science ®Google Scholar
• The Effectiveness of Methadone Maintenance Treatment, J. Ball, A. Ross. Springer-Verlag, New York 1991
   Google Scholar
• Batki S. L., Washburn A. M., Delucchi K., Jones R. T. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Dependence 1996; 41: 137–142
   PubMed Web of Science ®Google Scholar
• Baumgartner G. R., Rowen R. C. Clonidine versus chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Arch. Int. Med. 1987; 107: 880–884
   Google Scholar
• Bickel W. K., Stitzer M. L., Bigelow G. E., Liebson I. A., Jasinski D. R., Johnson R. E. Buprenorphine: Dose-related blockade of opioid challenge effects in opioid-dependent humans. J. Pharmacol. Exper. Ther. 1988; 247: 47–53
   PubMed Web of Science ®Google Scholar
• Blaine J. D., Thomas D. B., Barnett G., Whysner J. A., Renault P. F. Levo-alpha-acetylmethadol (LAAM): Clinical utility and pharmaceutical development. Substance Abuse: Clinical Problems and Perspectives, J. H. Lowinson, P. Ruiz. Williams and Wilkins, Baltimore 1981; 360–388
   Google Scholar
• Bolla K. I., Cadet J. L., London E. D. The neuropsychiatry of chronic cocaine abuse. J. Neuropsychiatry Clin. Neurosci. 1998; 10: 280–289
   PubMed Web of Science ®Google Scholar
• Brown L. S., Sawyer R. C., Li R., Cobb M. N., Colborn D. C., Narang P. K. Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Drug Alcohol Dependence 1996; 43: 71–77
   PubMed Web of Science ®Google Scholar
• Brunning J., Mumford J. P., Keaney F. P. Lofexidine in alcohol withdrawal states. Alcohol 1986; 21: 67
   Web of Science ®Google Scholar
• Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22(Suppl)49–59
   PubMed Web of Science ®Google Scholar
• Carroll K. M., Nich C., Ball S. A., McCance E. F., Frankfurter T. L., Rounsaville B. J. One year follow-up of disulfiram and psychotherapy for cocaine-alcohol abusers: Sustained effects of treatment, (in press)
   Google Scholar
• Carroll K. M., Nich C., Ball S. A., McCance E., Rounsaville B. J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93: 713–727
   PubMed Web of Science ®Google Scholar
• Carroll K. M., Rounsaville B. J., Gordon L. T., Nich C., Jatlow P., Bisighini R. M., Gawin F. H. Psychotherapy and pharmacotherapy for ambulatory cocaine abuses. Arch. Gen. Psychiatry 1994; 51: 177–187
   PubMed Web of Science ®Google Scholar
• Carroll K. M., Ziedonis D., O'Malley S. S., McCance-Katz E. F., Rounsaville B. R. Pharmacologic interventions for abusers of alcohol and cocaine: Disulfiram versus naltrexone. Am. J. Addict. 1993; 2: 77–79
   Google Scholar
• Carroll M. E., Lac S., Asencio M., Kragh R. Fluoxetine reduces intravenous cocaine self-administration in the rat. Pharmacol. Biochem. Behav. 1990; 35: 237–244
   PubMed Web of Science ®Google Scholar
• Charney D. S., Riordan C. E., Kleber H. D., Murburg M., Braverman P., Sternberg D. E., Heninger G. R., Redmond D. E. Clonidine and naltrexone: A safe, effective and rapid treatment of abrupt withdrawal from metha-done therapy. Arch. Gen Psychiatry 1982; 39: 1327–1332
   PubMed Web of Science ®Google Scholar
• Compton P. A., Wesson D. R., Charuvastra V. C., Ling W. Buprenorphine as a pharmacotherapy for opiate addiction. Am. J. Addict. 1996; 5: 1–11
   Web of Science ®Google Scholar
• Cornish J. W., Maany I., Fudala P. J., Neal S., Poole S. A., Volpicelli P., O'Brien C. P. Carbamazepine treatment for cocaine dependence. Drug Alcohol Dependence 1995; 38: 221–227
   PubMed Web of Science ®Google Scholar
• Covi L., Montoya I. D., Hess J., Kreiter N. Double-blind comparison of desipramine and placebo for treatment of cocaine dependence. Clin. Pharmacol. Ther. 1994; 55: 132–138
   Web of Science ®Google Scholar
• Diakogiannis I. A., Steinberg M., Kosten T. R. Mazindol treatment of cocaine abuse: A double-blind investigation. NIDA Res. Monogr. 1990; 105: 514
   PubMedGoogle Scholar
• Elenbaas R. M. Drug therapy reviews: Management of the disulfiram-alcohol reaction. Am. J. Hasp. Pharm. 1977; 34: 827–831
   PubMedGoogle Scholar
• Fagerstrom K. O., Melin B. Nicotine chewing gum in smoking cessation: efficiency, nicotine dependence, therapy duration, and clinical recommendations. NIDA Res. Monogr. 1985; 53: 102–109
   PubMedGoogle Scholar
• Ferry L. H., Robbins A. S., Scariati P. D., Masterson A., Abbey D. E., Burchette R. J. Enhancement of smoking cessation using the antidepressant bupropion hydrochloride (abstract). Circulation 1992; 86: 671
   Web of Science ®Google Scholar
• Finn P., Wilcock K. Levo-Alpha Acetyl Methadol (LAAM). J. Subst. Abuse Treat. 1998; 14: 559–564
   Web of Science ®Google Scholar
• Fiore M. C., Jorenby D. E., Baker T. B., Kenford S. L. Tobacco dependence and the nicotine patch: Clinical guidelines for effective use. JAMA 1992; 268: 2687–2694
   PubMed Web of Science ®Google Scholar
• Fiore M. C., Smith S. S., Jorenby D. E., Baker T. B. The effectiveness of the nicotine patch for smoking cessation: A meta analysis. JAMA 1994; 271: 1940–1946
   PubMed Web of Science ®Google Scholar
• Fox B. S. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Dependence 1997; 48: 153–158
   PubMed Web of Science ®Google Scholar
• Fox B. S., Kantak K. M., Edwards M. A. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Med. 1996; 2: 1129–1132
   PubMed Web of Science ®Google Scholar
• Fuller R. F., Branchey L., Brightwell D. R., Derman R. M., Emrick C. D., Iber F. L., James K. E., Lacoursiere R. B., Lee K. K., Lowenstein I., Maany I., Neiderhiser D., Nocks J. J., Shaw S. Disulfiram treatment of alcoholism: A Veteran's Administration cooperative study. JAMA 1986; 256: 1449–1455
   PubMed Web of Science ®Google Scholar
• Galanti L. M., Manigart P., Dubois P. Tobacco smoking and alcohol and drug consumption in a large, young, healthy population. Arch. Environ. Health 1998; 53: 156–160
   PubMed Web of Science ®Google Scholar
• Galloway G., Hayner G. Haight-Ashbury Free Clinics' drug detoxification protocols. Part 2: Opioid blockade. J. Psychoactive Drugs 1993; 25: 251–252
   PubMed Web of Science ®Google Scholar
• Garbutt J. C., West S. L., Carey T. S., Lohr K. N., Crews F. T. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 14: 1318–1325
   Web of Science ®Google Scholar
• Gawin F. H., Kleber H. D., Byck R., Rounsaville B. J., Kosten T. R., Jatlow P. I., Morgan C. Desipramine facilitation of initial cocaine abstinence. Arch. Gen. Psychiatry 1989; 36: 117–121
   Google Scholar
• Gawin F. H., Kleber H. D. Pharmacological treatment of cocaine abuse. Psychiatric Clin. N. Am. 1986; 9: 573–583
   PubMed Web of Science ®Google Scholar
• Gawin F., Riordan C., Kleber H. Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative report. Am. J. Drug Alcohol Abuse 1985; 11: 193–197
   PubMed Web of Science ®Google Scholar
• Ghodse H., Myles J., Smith S. E. Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. Br. J. Psychiatry 1994; 165: 370–374
   PubMed Web of Science ®Google Scholar
• Giannini A. J., Baumgartel P. Bromocriptine in cocaine withdrawal. J. Clin. Pharmacol. 1987; 27: 267–270
   PubMed Web of Science ®Google Scholar
• Gold M. S., Redmond D. E., Kleber H. D. Clonidine for opiate withdrawal. Lancet 1978; 1: 929–930
   PubMed Web of Science ®Google Scholar
• Gorelick D. A. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Dependence 1997; 48: 159–165
   PubMed Web of Science ®Google Scholar
• Grabowski J., Rhoades H., Elk R., Schitz J., Davis C., Creson D., Kirby K. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: 2 placebo-controlled, double-blind trials. J. Clin. Psychopharmacol. 1995; 15: 163–174
   PubMed Web of Science ®Google Scholar
• Haberny K. A., Walsh S. L., Ginn D., Wilkins J. N., Garner J. E., Setoda D., Bigelow G. E. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend. 1995; 39: 55–62
   PubMed Web of Science ®Google Scholar
• Hald J., Jacobsen E., Larsen V. The sensitizing effect of tetra-ethylthiuram disulfide (Antabuse) to ethyl alcohol. Acta Pharmacol. Toxicol. 1948; 4: 285–296
   Google Scholar
• Halikas J., Kemp K., Kuhn K., Carlson G., Crea F. Carbamazepine for cocaine addiction?. Lancet 1989; 1: 623–624
   PubMed Web of Science ®Google Scholar
• Hall S. M., Hall R. G., Ginsberg D. Pharmacology and behavioral treatment for cigarettes smoking. Progress in Behavior Modification, M. Hersen, R. M. Eisler, P. M. Miller. Sage, Newbury Park, CA 1990; 86–118
   Google Scholar
• Hall S. M., Munoz R. F., Reus V., Sees K. Nicotine, negative affect, and depression. J. Consult. Clin. Psychol. 1993; 61: 761–767
   PubMed Web of Science ®Google Scholar
• Hall S. M., Reus V. I., Munoz R. F., Sees K. L., Humfleet G., Hartz D. T., Frederick S., Triffleman E. Nortriplyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry 1998; 55: 683–690
   PubMed Web of Science ®Google Scholar
• Handelsman L., Rosenblum A., Palij M., Magura S., Foote J., Lovejoy M., Stimmel B. Bromocriptine for cocaine dependence. Am. J. Addict. 1997; 6: 54–64
   PubMed Web of Science ®Google Scholar
• Hatsukami D. K., Huber M., Callies A., Skoog K. Physical dependence on nicotine gum: Effect of duration of use. Psychopharmacology 1993; 111: 449–456
   PubMed Web of Science ®Google Scholar
• Helander A., Carlsson S. Use of leukocyte aldehyde dehydrogenase activity to monitor inhibitory effect of disulfiram treatment in alcoholism. Alcoholism Clin. Exper. Res. 1990; 14: 48–52
   PubMed Web of Science ®Google Scholar
• Henningfield J. E., Stapleton J. M., Benowitz N. L., Grayson R. R., London E. D. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Dependence 1993; 33: 23–29
   PubMed Web of Science ®Google Scholar
• Higgins S. T., Budney A. J., Bickel W. K., Hughes J. R., Foerg F. Disulfiram therapy in patients abusing cocaine and alcohol. Am. J. Psychiatry 1993; 150(4)675–676
   PubMed Web of Science ®Google Scholar
• Hillbom M., Tokola R., Kuusela V., Karkkainen P., Kalli-Lemma L., Pilke A., Kaste M. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol 1989; 6: 223–226
   PubMed Web of Science ®Google Scholar
• Hjalmarson A., Franzon M., Westin A., Wiklund O. Effect of nicotine spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch. Int. Med. 1994; 154: 2567–2572
   PubMedGoogle Scholar
• Hughes J. R. Non-nicotine pharmacotherapies for smoking cessation. J. Drug Devel. 1996; 9: 197–203
   Google Scholar
• Jasinski D. R., Pevnick J. S., Griffith J. D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry 1978; 35: 510–516
   Web of Science ®Google Scholar
• Jenkins S. W., Warfield N. A., Blaine J. D., Cornish J., Ling W., Rosen M. I., Urschel H., III, Wesson D., Ziedonis D. A pilot trial of gepirone vs. placebo in the treatment of cocaine dependency. Psychopharmacol. Bull. 1992; 28: 21–26
   PubMedGoogle Scholar
• Johansson C. J., Olsson P., Bende M., Carlsson T., Gunnarsson P. O. Absolute bioavailability of nicotine applied to different nasal regions. Eur. J. Clin. Pharmacol. 1991; 41: 585–588
   PubMed Web of Science ®Google Scholar
• Johnson R. E., Eissenberg T., Stitzer M. L., Strain E. C., Liebson I. A., Bigelow G. E. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Dependence 1995; 40: 27–35
   PubMed Web of Science ®Google Scholar
• Johnson R. E., Fudala P. J., Jaffe J. H. A controlled trial of buprenorphine for opioid dependence. JAMA 1992; 267: 2750–2755
   PubMed Web of Science ®Google Scholar
• Kampman K., Volpicelli J. R., Alterman A., Cornish J., Weinrieb R., Epperson L., Sparkman T., O'Brien C. P. Amantadine in the early treatment of cocaine dependence: A double-blind, placebo-controlled trial. Drug Alcohol Dependence 1996; 41: 25–33
   PubMed Web of Science ®Google Scholar
• Khan A., Mumford J. P., Rogers G. A., Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Dependence 1997; 44: 57–61
   PubMed Web of Science ®Google Scholar
• Kleber H. D. Opioids: detoxification. Textbook of Substance Abuse Treatment, M. Galanter, H. D. Kleber. American Psychiatric Press, Washington, DC 1994
   Google Scholar
• Kleber H. D., Topazian M., Gaspari J., Riordan C. E., Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am. J. Drug Alcohol Abuse 1987; 13: 1–17
   PubMed Web of Science ®Google Scholar
• Kleber H. D. Detoxification from narcotics. Substance Abuse: Clinical Problems and Perspectives, J. H. Lowinson, P. Ruiz. William and Wilkins, Baltimore 1981; 317–338
   Google Scholar
• Koe B. K. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J. Pharmacol. Exper. Ther. 1976; 199: 649–661
   PubMed Web of Science ®Google Scholar
• Kosten T. A., Decaprio J. L., Nestler E. J. Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure. Psychopharmacology 1996; 128: 304–312
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Schottenfeld R. S., Ziedonis D., Falcioni J. Buprenorphine vs. methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 1993a; 181: 358–364
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Steinberg M., Diakogiannis I. Crossover trial of mazindol for cocaine dependence. Am. J. Addict. 1993b; 2: 161–164
   Google Scholar
• Kosten T. R., Gawin F. H., Gordon L. T., Hogan I. F., Kleber H. D. An open trial of sertraline for cocaine abuse. Am. J. Addict. 1992a; 1: 349–353
   Google Scholar
• Kosten T. R., Morgan C. M., Falcioni J., Schottenfeld R. S. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch. Gen. Psychiatry 1992b; 49: 894–898
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Kleber H. D., Morgan C. H. Treatment of cocaine abuse using buprenorphine. Biol. Psychiatry 1989; 26: 637–639
   PubMed Web of Science ®Google Scholar
• Kosten T. R., Kleber H. D. Strategies to improve compliance with narcotic antagonists. Am. J. Drug Alcohol Abuse 1984; 10: 249–266
   PubMed Web of Science ®Google Scholar
• Kranzler H. R., Babor T. F., Moore P. Alcohol use disorders. Psychiatry, A. Tasman, J. Kay, J. R. Lieberman. W. B. Saunders Company, Philadelphia 1995a; 755–778
   Google Scholar
• Kranzler H. R., Bauer L. O., Hersh D., Klinghoffer V. Carbamazepine treatment of cocaine dependence: A placebo-controlled trial. Drug Alcohol Dependence 1995b; 38: 203–211
   PubMed Web of Science ®Google Scholar
• Kranzler H. R., Burleson J. A., Del Boca F. K., Babor T. F., Korner P., Brown J., Bohn M. Buspirone treatment of anxious alcoholics. Arch. Gen Psychiatry 1994; 51: 720–731
   PubMed Web of Science ®Google Scholar
• Kraus M. L., Gottlieb L. D., Horwitz R. L., Anscher M. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N. Engl. J. Med. 1985; 313: 905–909
   PubMed Web of Science ®Google Scholar
• Kreek M. J., Garfield J. W., Gutjahr C. L., Guisti L. M. Rifampin induced methadone withdrawal. N. Engl. J. Med. 1976; 294: 1104–1106
   PubMed Web of Science ®Google Scholar
• Krishnan-Sarin S., Rosen M. I., O'Malley S. S. Naloxone challenge in smokers. Arch. Gen. Psychiatry 1999; 56: 663–668
   PubMed Web of Science ®Google Scholar
• Kuhar M. J., Ritz M. C., Boja J. W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends in Neurosci. 1991; 14: 299–302
   PubMed Web of Science ®Google Scholar
• Kuhlman J. J., Levine B., Johnson R. E., Fudala P. J., Cone E. J. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93: 549–559
   PubMed Web of Science ®Google Scholar
• Lambie D. G., Johnson R. H., Vijayasenan M. E., Whiteside E. A. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Austr. N. Z. J. Psychiatry 1980; 14: 213–215
   PubMed Web of Science ®Google Scholar
• Lee E. W., D'Alonzo G. E. Cigarette smoking, nicotine addiction, and its pharmacologic treatment. Arch. Int. Med. 1993; 153: 34–48
   PubMedGoogle Scholar
• Levin F. R., Evans S. M., McSowell D. M., Kleber H. D. Methlyphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J. Clin. Psychiatry 1998; 59: 300–305
   PubMed Web of Science ®Google Scholar
• Levin F. R., Lehman A. F. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J. Clin. Psychopharmacol. 1991; 111: 374–378
   Google Scholar
• Lewis J. W. Buprenorphine. Drug Alcohol Dependence 1985; 14: 363–372
   PubMed Web of Science ®Google Scholar
• Lin S. K., Strang J., Su L. W., Tsai C. J., Hu W. H. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drag Alcohol Dependence 1997; 48: 127–133
   PubMed Web of Science ®Google Scholar
• Littleton J. Acamprosate in alcohol dependence: How does it Work?. Addiction 1985; 90: 1179–1188
   Google Scholar
• Magura S., Kang S. Y., Rosenblum A., Handelsman L., Foote J. Gender differences in psychiatric comorbidity among cocaine-using opiate addicts. J. Addict. Dis. 1998; 17: 49–61
   PubMed Web of Science ®Google Scholar
• Magura S., Rosenblum A. Modulating effect of cocaine use on alcohol use. Addict. Behav 2000; 25: 117–122
   PubMed Web of Science ®Google Scholar
• Malcolm R., Ballenger J. C., Sturgis E. T., Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am. J. Psychiatry 1989; 146: 617–621
   PubMed Web of Science ®Google Scholar
• Malison R. T., McCance E. F., Carpenter L. L., Baldwin R. M., Seibyl J. P., Price L. H., Kosten T. R., Innis R. B. [1231] ß-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology 1998; 137: 321–325
   PubMed Web of Science ®Google Scholar
• Margolin A., Kosten T. R., Avants S. K., Wilkins J., Ling W., Beckson M., Arndt I. O., Cornish J., Ascher J. A., Li S. H. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Dependence 1995; 40: 125–131
   PubMed Web of Science ®Google Scholar
• Margolin A., Kosten T., Petrakis I., Avants S. K., Kosten T. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch. Gen Psychiatry 1991; 48: 87
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Kosten T. R. Psychopharmacological treatments. Clinical Textbook of Addictive Disorders, S. H. Miller, R. J. Frances. Guilford Press, New York 1998; 596–624
   Google Scholar
• McCance-Katz E. F., Kosten T. R., Jatlow P. I. Chronic disulfiram treatment effects on intranasal cocaine administration—initial results. Biol. Psychiatry 1998a; 43: 540–543
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Kosten T. R., Jatlow P. I. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone—a multiple-dose study. Biol. Psychiatry 1998b; 44: 250–259
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Kosten T. R., Jatlow P. I. Disulfiram effects on acute cocaine administration. Drug Alcohol Dependence 1998c; 52: 27–39
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Rainey P. M., Jatlow P., Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J. Acquired Immune Defic. Syndr. Human Retroviral. 1998d; 18: 435–443
   PubMedGoogle Scholar
• Mello N. K., Negus S. S. The effects of buprenorphine on self-administration of cocaine and heroin “speedball” combinations and heroin alone by rhesus monkeys. J. Pharmacol. Exper. Ther. 1998; 285: 444–456
   PubMed Web of Science ®Google Scholar
• Meyer R. E. How to understand the relationship between psychopathology and addictive disorders: Another example of the chicken and the egg. Psychopathology and Addictive Disorders, R. E. Meyer. Guilford Press, New York 1986; 3–16
   Google Scholar
• Mirin Chair S. M. Practice guideline for the treatment of patients with substance use disorders: Alcohol, cocaine, opioids. American Psychiatric Association Practice Guidelines. American Psychiatric Press, Inc., Washington, DC 1995; 40–41
   Google Scholar
• Montoya I. D., Preston K., Rotham R., Cone E., Gorelick D. A. Safety and efficacy of bupropion in combination with bromocriptine for treatment of cocaine dependence. NIDA Res. Monogr. 1994; 153: 304
   Google Scholar
• O'Connor P. G., Oliveto A. H., Shi J. M., Triffleman E. G., Carroll K. M., Kosten T. R., Rounsaville B. J., Pakes J. A., Schottenfeld R. S. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am. J. Med. 1998; 105: 100–105
   PubMed Web of Science ®Google Scholar
• O'Connor P. G., Waugh M. E., Carroll K. M., Rounsaville B. J., Diakogiannis I. A., Schottenfeld R. S. Primary care-based ambulatory opioid detoxification: The results of a clinical trial. J. Gen. Int. Med. 1995; 10: 255–260
   PubMed Web of Science ®Google Scholar
• O'Malley S. S., Jaffe A. J., Chang G., Rode S., Schottenfeld R. S., Meyer R. E., Rounsaville B. J. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch. Gen. Psychiatry 1996; 53: 217–224
   PubMed Web of Science ®Google Scholar
• O'Malley S. S., Jaffe A. J., Chang G., Schottenfeld R. S., Meyer R. E., Rounsaville B. J. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch. Gen. Psychiatry 1992; 49: 881–887
   PubMed Web of Science ®Google Scholar
• Oliveto A., Kosten T. R., Schottenfeld R., Falcioni J., Ziedonis D. Desipramine. amantadine. or fluoxetine in buprenorphine-maintained cocaine users. J. Subst. Abuse 1995; 12: 423–428
   Google Scholar
• Palmer K. J., Buckley M. M., Faulds D. Transdermal nicotine: A review of its phamacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44: 498–529
   PubMed Web of Science ®Google Scholar
• Petrakis I., Carroll E. M., Nich C., Gordon L., Kosten T., Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drugs Alcohol Dependence 1998; 50: 221–226
   PubMed Web of Science ®Google Scholar
• Petrakis J. L., Carroll E. M., Nich C., Gordon L. T., McCance-Katz E. F., Frankfurter T., Rounsaville B. J. Disulfiram treatment for cocaine dependence in methadone maintained opioid addicts. Addiction 2000; 95: 219–228
   PubMed Web of Science ®Google Scholar
• Post R. M., Kopanda R. T. Cocaine kindling and psychosis. Am. J. Psychiatry 1976; 133: 627–634
   PubMed Web of Science ®Google Scholar
• Quigley A. J., Bredemeyer D. E., Seow S. S. A case of buprenorphine abuse. Med. J. Austr. 1984; 142: 425–426
   Web of Science ®Google Scholar
• Richardson N., Roberts D. Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci. 1991; 49: 833–840
   PubMed Web of Science ®Google Scholar
• Ritz M. C., Cohen E., Kuhar M. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: A structure-activity study. Life Sci. 1990; 46: 635–645
   PubMed Web of Science ®Google Scholar
• Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol. Psychiatry 1998; 44: 633–637
   PubMed Web of Science ®Google Scholar
• Roy-Byrne P. P., Ward N. G., Donnelly P. J. Valproate in anxiety and withdrawal syndromes. J. Clin. Psychiatry 1989; 50(Suppl)44–48
   PubMedGoogle Scholar
• Sachs D. P. L. Advances in smoking cessation treatment. Curr. Pulmonol. 1991; 12: 139–198
   Google Scholar
• Sass H., Soyka M., Mann K., Zieglgansberg W. Relapse prevention by acamprosate. Arch. Gen. Psychiatry 1996; 53: 673–680
   PubMed Web of Science ®Google Scholar
• Schottenfeld R. S., Pakes J., Ziedonis D. M., Kosten T. Buprenorphine: Dose related effects on cocaine and opiate use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry 1993; 34: 66–74
   PubMed Web of Science ®Google Scholar
• Schneider N. G., Olmstead R., Mody F. V., Doan K., Franzon M., Jarvik M. E., Steinberg C. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90: 1671–1682
   PubMed Web of Science ®Google Scholar
• Self D. W., Barnhart W. J., Lehman D. A., Nestler E. J. Opposite modulation of cocaine-seeking behavior by D1 and D2-like dopamine receptor agonists. Science 1996; 271: 1586–1589
   PubMed Web of Science ®Google Scholar
• Sellers E. M., Higgins G. A., Sobell M. B. 5-HT and alcohol abuse. Trends Pharmacol. Sci. 1992; 13: 69–75
   PubMed Web of Science ®Google Scholar
• Sellers E. M., Naranjo C. A., Harrison M., Devenyi P., Roach C., Sykora K. Diazepam loading: Simplified treatment of alcohol withdrawal. Clin. Pharmacol. Ther. 1983; 34: 822–826
   PubMed Web of Science ®Google Scholar
• Singha A., Oliveto A., McCance E., Petrakis I., Stine S., Kosten T. R. Effects of cocaine prior to and during bupropion maintenance in cocaine abusers. NIDA Res. Monogr 1998; 178: 137
   Google Scholar
• Stine S. M., Krystal J. H., Kosten T. R., Charney D. S. Mazindol treatment for cocaine dependence. Drug Alcohol Dependence 1995; 39: 245–252
   PubMed Web of Science ®Google Scholar
• Strain E. C., Stoller K., Walsh S. L., Bigelow G. E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology 2000; 148: 374–383
   PubMed Web of Science ®Google Scholar
• Strain E. C., Stitzer M. L., Liebson I. A., Bigelow G. E. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994; 116: 401–406
   PubMed Web of Science ®Google Scholar
• Tennant F. S., Sagherian A. A. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch. Int. Med. 1987; 147: 109–112
   PubMed Web of Science ®Google Scholar
• Tollefson G. D., Montague-Clouse J., Tollefson S. L. Treatment of comorbid generalized anxiety in a recently detoxified alcohol population with a selective serotonergic drug (buspirone). J. Clin. Psychopharmacol 1992; 12: 19–26
   PubMed Web of Science ®Google Scholar
• Van Etten M. L., Higgins S. T., Budney A. J., Bickel W. K., Hughes J. R., Foerg F. Disulfiram therapy in patients abusing cocaine and alcohol. NIDA Res. Monogr. 1994; 141: 443
   Google Scholar
• Vining E., Kosten T. R., Kleber H. D. Clinical utility of rapid clonidine naltrexone detoxification for opioid abusers. Br. J. Addict. 1988; 83: 567–575
   PubMedGoogle Scholar
• Volpicelli J., Alterman A. I., O'Brien C. P., Hayashida M. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 1992; 49: 867–880
   PubMed Web of Science ®Google Scholar
• Weddington W. W., Brown B. S., Haertzen C. A., Mahaffrey J. R., Kolar A. F., Jaffe J. H. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am. J. Drug Alcohol Abuse 1991; 17: 137–152
   PubMed Web of Science ®Google Scholar
• Whitworth A. B., Fischer F., Lesch O. M., Nimmerrichter A., Oberbauer H., Platz T., Potgieter A., Walter H., Fleischhaker W. W. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438–1442
   PubMed Web of Science ®Google Scholar
• Wilde M. I., Wagstaff A. J. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997; 53: 1038–1053
   PubMed Web of Science ®Google Scholar
• Wines J. D., Weiss R. D. Opioid withdrawal during risperidone treatment. J. din. Psychopharmacol. 1999; 19: 265–267
   PubMed Web of Science ®Google Scholar
• Wright C., Moore R. D. Disulfiram treatment of alcoholism. Am. J. Med. 1990; 88: 647–655
   PubMed Web of Science ®Google Scholar
• Zeise M. L., Kasparov S., Capogna M., Zieglgansberger W. Acamprosate (calciumacetylhomotaurinate) decrease postsynaptic potentials in the rat neocortex: Possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. 1993; 231: 47–52
   PubMed Web of Science ®Google Scholar
• Zernig G., O'Laughlin I. A., Fibiger H. C. Nicotine and heroin augment cocaine-induced dopamine overflow in nucleus accumbens. Eur. J. Pharmacol. 1997; 337: 1–10
   PubMed Web of Science ®Google Scholar